Medications for Early-Onset Alzheimer's Disease in a 25-Year-Old Female with Glycogen Storage Disorder

1. First-Line Symptomatic Medications

A. Cholinesterase Inhibitors (ChEIs)

• Tacrine (the original ChEI) was discontinued in 2013 due to hepatotoxicity - this is particularly relevant here given GSD.
• ChEIs were originally approved for mild-to-moderate AD, but efficacy has also been demonstrated in severe AD and Lewy body dementia.
• Combining a ChEI with memantine provides better outcomes than either alone.

B. Memantine (Namenda)

• Mechanism: Low-to-moderate affinity, uncompetitive NMDA (glutamate) receptor antagonist; reduces excitotoxicity from pathologically elevated glutamate.
• Dose: Start 5 mg daily, increase by 5 mg weekly to target dose of 20 mg daily (10 mg twice daily).
• Licensed for: Moderate-to-severe AD.
• Combination: Adding memantine to an existing ChEI provides incremental benefit over either drug alone.
• Memantine is primarily renally excreted (80% unchanged) - this is favorable in GSD where hepatic involvement may be present.

2. Disease-Modifying Therapies (Anti-Amyloid Antibodies) - Newer Agents

3. Management of Behavioral/Psychological Symptoms (BPSD)

4. Critical Considerations Given Glycogen Storage Disorder (GSD)

• GSD Type I (von Gierke): Liver, kidney - risk of hypoglycemia, lactic acidosis, hyperuricemia. Avoid drugs that stress hepatic metabolism.
• GSD Type II (Pompe disease): Muscle and heart - enzyme replacement therapy (alglucosidase alfa) is the treatment. Respiratory and cardiac monitoring essential.
• GSD Type III (Cori): Liver + muscle - hepatomegaly, myopathy.
• GSD Type V (McArdle): Skeletal muscle only - fewer drug interactions.

• Donepezil - Metabolized by CYP2D6 and CYP3A4 in the liver. In GSD with significant hepatic involvement (Types I, III, VI), monitor liver function. However, it has no direct hepatotoxicity unlike tacrine.
• Rivastigmine transdermal patch - Undergoes minimal hepatic metabolism (primarily via cholinesterase-mediated hydrolysis in the blood); this is the preferred ChEI in patients with hepatic compromise from GSD, as it largely bypasses hepatic CYP metabolism.
• Galantamine - Metabolized by CYP2D6 and CYP3A4. Moderate hepatic impairment: max dose 16 mg/day. Severe hepatic impairment: contraindicated.
• Memantine - Minimal hepatic metabolism; primarily renally excreted. Safe option in hepatic GSD.
• Anti-amyloid antibodies (lecanemab, donanemab) - Monoclonal antibodies metabolized via proteolysis, not hepatic CYP enzymes. They do not carry the same hepatic interaction concerns. However, their use in a 25-year-old requires careful biomarker confirmation and specialist input.
• Hypoglycemia awareness: In GSD types with hypoglycemia risk (Type I), any drug causing anorexia or nausea (all ChEIs) could worsen nutritional and glycemic control. Rivastigmine patch tends to have fewer GI effects than oral formulations.
• Enzyme Replacement Therapy (ERT) for Pompe/GSD Type II (alglucosidase alfa, avalglucosidase alfa) - These are the disease-specific treatments for GSD itself and must continue alongside any AD treatment. No direct pharmacokinetic interactions with ChEIs or memantine are documented, but vigilance is needed.

5. Non-Pharmacologic and Supportive Measures

• Regular aerobic exercise (within limits set by GSD type - restricted in muscle GSDs like McArdle disease)
• Cognitive stimulation therapy
• Structured daily routines
• Management of cardiovascular risk factors
• Hearing assessment and correction
• Treatment of sleep disorders
• Nutritional support (especially critical in GSD - dietitian involvement mandatory)
• Genetic counseling for familial AD

6. Recommended Treatment Algorithm for This Patient

Step 1: Confirm diagnosis
  → Genetic testing (PSEN1/PSEN2/APP mutations)
  → CSF biomarkers (Aβ42, tau, phospho-tau) or amyloid PET
  → Identify GSD subtype precisely

Step 2: Initiate symptomatic treatment
  → First-line: Rivastigmine transdermal patch (9.5 mg/24h)
     [preferred in GSD due to minimal hepatic metabolism]
  → Add memantine (titrate to 20 mg/day) if moderate-severe symptoms
     [safe in hepatic GSD - renally excreted]

Step 3: Consider disease-modifying therapy
  → If early AD confirmed with amyloid PET/CSF:
     → Lecanemab or donanemab (requires APOE4 genotyping, MRI monitoring)
     → Note: Evidence base is in adults aged 50-80; extrapolation to age 25 is off-label

Step 4: Manage comorbidity
  → Continue GSD-specific treatment (ERT if Pompe disease)
  → Nutritional team for GSD dietary management
  → Monitor for drug-disease interactions per GSD subtype

Key Warnings

• Tacrine is absolutely contraindicated - withdrawn due to hepatotoxicity, especially dangerous with hepatic GSD.
• Galantamine should be avoided in severe hepatic impairment from GSD.
• Anti-amyloid antibodies have not been studied in GSD or in patients aged 25 - use requires multidisciplinary specialist consensus.
• All second-generation antipsychotics carry an FDA black box warning for increased mortality in dementia patients - use only for severe, refractory BPSD.
• A 25-year-old with AD warrants referral to a specialized memory/neurodegenerative disease center, ideally one with expertise in genetic/familial AD and metabolic disorders.

• 2024 meta-analysis on AD drug efficacy (Chen Y et al., Medicine, 2024)
• TRAILBLAZER-ALZ 2: Donanemab in early AD (JAMA, 2023)
• Lecanemab Phase 3 safety update (Alzheimers Res Ther, 2024)
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry
• Maudsley Prescribing Guidelines in Psychiatry, 15th ed.
• Goldman-Cecil Medicine International Edition, 2025
• Harrison's Principles of Internal Medicine, 22nd ed.

Disclaimer: This is clinical decision-support information. A 25-year-old with suspected early-onset Alzheimer's and GSD is an extremely unusual and complex case. All treatment decisions must be made by a multidisciplinary team including a neurologist specializing in neurodegenerative disease, a metabolic/genetic specialist, and a clinical pharmacist.